We read with interest the recent article by Liu et al, in Circulation Research, on the mechanism underlying the antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia (CPVT). 1 They conclude that Na ϩ channel block but not inhibition of the cardiac ryanodine receptor (RyR2) has a key role in the antiarrhythmic effects of flecainide in CPVT, because they found flecainide suppresses triggered activity without a reduction of Ca 2ϩ waves in RyR2 R4496Cϩ/Ϫ mice. However, we have previously reported that flecainide directly inhibits RYR2 and thereby prevents CPVT. 2 Evidence that flecainide reduces the frequency of triggered beats to a greater extent than that of spontaneous Ca 2ϩ waves in cardiac calsequestrin Casq2 null (Casq2 Ϫ/Ϫ ) mice, another model of CPVT, led us to propose a dual mode of flecainide action in CPVT: suppression of spontaneous Ca 2ϩ release from sarcoplasmic reticulum by RyR2 inhibition and suppression of triggered beats by Na ϩ channel block. 2 Our studies with a range of sodium channel blockers support a role for RyR2 block in this setting. In our first report, we found that lidocaine, which does not inhibit RyR2, fails to suppress CPVT at a dose that produces similar Na ϩ channel block to a dose of flecainide that completely suppresses CPVT, 2 which supports a direct role for RyR2 inhibition in this setting. The importance of RyR2 inhibition is further corroborated by our recent study, which tested the effects of all class I antiarrhythmic drugs clinically available in the Unites States in Casq2 Ϫ/Ϫ mice. 3 We found that RyR2 inhibition and Ca 2ϩ wave suppression in vitro determined the antiarrhythmic efficacy against CPVT in vivo. 3 The importance of RyR2 inhibition for preventing CPVT has also been confirmed by the recent report of the Chen group. 4 One of the points of difference between the data of Liu et al and our work is the effect of flecainide on sarcoplasmic reticulum Ca 2ϩ sparks: no apparent effect in RyR2 R4496Cϩ/Ϫ cells in the study by Liu et al 1 and an increase in Ca 2ϩ spark frequency and reduction of spark amplitude, width, and overall spark mass in mouse and rat myocytes in our studies. 5, 6 The discrepancy may relate to experimental conditions, because the basal Ca 2ϩ spark frequency in the experiments by Liu et al is several fold higher than that of our experiments. 1,5 If Ca 2ϩ spark frequency is already very high, it may be difficult to detect any further increases caused by flecainide.
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Another possible explanation for the reported discrepancy is that flecainide may be less effective against mutant RyR2 R4496Cϩ/Ϫ channels than wild-type RyR2 channels in the setting of Casq2 deletion. However, the Fishman group 7 has reported that flecainide is effective in suppressing Ca 2ϩ waves in Purkinje cells from the same RyR2 R4496Cϩ/Ϫ mouse model studied by Liu et al. 1 Furthermore, we reported that flecainide and propafenone (which also blocks RyR2 channels) were effective in CPVT patients carrying mutations in RYR2, 2, 3 whereas other sodium channel blockers that did not inhibit RyR2 in our experiments were ineffective in CPVT patients. 8 -10 Taken together, these clinical and experimental findings suggest that both Na ϩ channel block and RyR2 inhibition are important for the antiarrhythmic effects of flecainide in CPVT. The interesting results reported by Liu et al 1 show that more experiments are needed to fully define the mechanisms of drug action in CPVT patients. 
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